Loading clinical trials...
Loading clinical trials...
Alternating Neoadjuvant Gemcitabine-Nab-Paclitaxel and Nanoliposomal Irinotecan (Nal-IRI) With 5-Fluorouracil and Folinic Acid (Leucovorin) Regimens in Resectable and Borderline Resectable Pancreatic Cancer
Conditions
Interventions
Gemcitabine
nab paclitaxel
+3 more
Locations
1
United States
Virginia mason medical Center
Seattle, Washington, United States
Start Date
September 17, 2018
Primary Completion Date
September 17, 2021
Completion Date
September 17, 2022
Last Updated
January 27, 2021
NCT06423326
NCT04389632
NCT04895709
NCT05825066
NCT07409272
NCT04605913
Lead Sponsor
Benaroya Research Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions